NZ513679A - Epitodes or mimotopes derived from the C-epsilon-2 domain of IgE, antagonists thereof, and their therapeutic uses - Google Patents

Epitodes or mimotopes derived from the C-epsilon-2 domain of IgE, antagonists thereof, and their therapeutic uses

Info

Publication number
NZ513679A
NZ513679A NZ513679A NZ51367900A NZ513679A NZ 513679 A NZ513679 A NZ 513679A NZ 513679 A NZ513679 A NZ 513679A NZ 51367900 A NZ51367900 A NZ 51367900A NZ 513679 A NZ513679 A NZ 513679A
Authority
NZ
New Zealand
Prior art keywords
epitodes
epsilon
ige
antagonists
domain
Prior art date
Application number
NZ513679A
Inventor
Michael Dyson
Alan Lamont
Sean Mason
Roger Randall
William Gordon Turnell
Mechelen Marcelle Paulette Van
Y De Bassols Carlota Vinals
Martin Friede
Judith Greenwood
Ellen Hewitt
Original Assignee
Smithkline Beecham Biolog S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9907151.6A external-priority patent/GB9907151D0/en
Priority claimed from GBGB9910538.9A external-priority patent/GB9910538D0/en
Priority claimed from GBGB9910537.1A external-priority patent/GB9910537D0/en
Priority claimed from GBGB9918594.4A external-priority patent/GB9918594D0/en
Priority claimed from GBGB9918603.3A external-priority patent/GB9918603D0/en
Priority claimed from GBGB9921046.0A external-priority patent/GB9921046D0/en
Priority claimed from GBGB9921047.8A external-priority patent/GB9921047D0/en
Priority claimed from GBGB9925619.0A external-priority patent/GB9925619D0/en
Priority claimed from GBGB9927698.2A external-priority patent/GB9927698D0/en
Application filed by Smithkline Beecham Biolog S filed Critical Smithkline Beecham Biolog S
Publication of NZ513679A publication Critical patent/NZ513679A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
NZ513679A 1999-02-25 2000-02-22 Epitodes or mimotopes derived from the C-epsilon-2 domain of IgE, antagonists thereof, and their therapeutic uses NZ513679A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9907151.6A GB9907151D0 (en) 1999-03-29 1999-03-29 Therapeutic antibody composition and use
GBGB9910538.9A GB9910538D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions ansd uses
GBGB9910537.1A GB9910537D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions and uses
GBGB9918594.4A GB9918594D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918603.3A GB9918603D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9921046.0A GB9921046D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody composition & use
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
GBGB9925619.0A GB9925619D0 (en) 1999-10-29 1999-10-29 Vaccine
GBGB9927698.2A GB9927698D0 (en) 1999-11-23 1999-11-23 Therapeutic antibody

Publications (1)

Publication Number Publication Date
NZ513679A true NZ513679A (en) 2001-09-28

Family

ID=27579426

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ513679A NZ513679A (en) 1999-02-25 2000-02-22 Epitodes or mimotopes derived from the C-epsilon-2 domain of IgE, antagonists thereof, and their therapeutic uses

Country Status (19)

Country Link
EP (1) EP1155037A1 (en)
JP (1) JP2004538238A (en)
KR (1) KR20020007313A (en)
CN (1) CN1348466A (en)
AR (1) AR029336A1 (en)
AU (1) AU2672700A (en)
BR (1) BR0008963A (en)
CA (1) CA2363637A1 (en)
CO (1) CO5210906A1 (en)
CZ (1) CZ20013082A3 (en)
HK (1) HK1044004A1 (en)
HU (1) HUP0200049A2 (en)
IL (1) IL145024A0 (en)
MX (1) MXPA01008613A (en)
NO (1) NO20014130L (en)
NZ (1) NZ513679A (en)
PL (1) PL350993A1 (en)
TR (1) TR200102506T2 (en)
WO (1) WO2000050460A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
US20030199671A1 (en) * 2001-04-18 2003-10-23 Rondon Isaac Jesus Binding molecules for Fc-region polypeptides
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
JP2010519194A (en) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ Binding elements for IgE molecules
AR065368A1 (en) * 2007-02-15 2009-06-03 Astrazeneca Ab ANTIBODIES FOR IGE MOLECULES
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
AU2019341095A1 (en) * 2018-09-21 2021-05-20 Animal Allergy Clinical Laboratories Inc. Anti-IgE antibody specifically binding to membrane-bound IgE antibody of IgE antibody-producing B cells and method for diagnosing and treating allergic symptoms using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides

Also Published As

Publication number Publication date
HK1044004A1 (en) 2002-10-04
EP1155037A1 (en) 2001-11-21
IL145024A0 (en) 2002-06-30
PL350993A1 (en) 2003-02-24
KR20020007313A (en) 2002-01-26
HUP0200049A2 (en) 2002-05-29
CA2363637A1 (en) 2000-08-31
NO20014130D0 (en) 2001-08-24
NO20014130L (en) 2001-09-13
CN1348466A (en) 2002-05-08
CZ20013082A3 (en) 2002-02-13
AU2672700A (en) 2000-09-14
WO2000050460A1 (en) 2000-08-31
CO5210906A1 (en) 2002-10-30
BR0008963A (en) 2001-11-27
JP2004538238A (en) 2004-12-24
TR200102506T2 (en) 2002-06-21
AR029336A1 (en) 2003-06-25
MXPA01008613A (en) 2003-06-24

Similar Documents

Publication Publication Date Title
NZ513680A (en) Epitodes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
ZA200004362B (en) Use of CRF antagonists and related compositions.
IL144147A0 (en) Regulators of the pct or smoothened pathway, compositions and uses related thereto
EE05107B1 (en) A tyrosine kinase inhibiting compound, a pharmaceutical composition comprising it, and use of the compound
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
ID28846A (en) 2-FENILBENZIMIDAZOL AND 2_FENILINDOL, THE MAKING AND USE OF IT
HUP0202049A3 (en) Indole derivatives and their use for the treatment of osteoporosis amongst other applications
ID30116A (en) PIRIDOPIRANOAZEPIN DECREASES, THE PRODUCTION AND USE OF THERAPY
PL338004A1 (en) Derivatives of azetidinylpropylpiperidine, intermediate compounds and application of such derivatives as antagonists of tachykinins
HK1043059A1 (en) Tumor necrosis factor antagonists and their use inendometriosis.
PL351617A1 (en) Substituted benzoylisoxazoles and the use thereof as herbicides
ZA200204635B (en) Fragments and antagonists of heat shock protein 60.
NZ513679A (en) Epitodes or mimotopes derived from the C-epsilon-2 domain of IgE, antagonists thereof, and their therapeutic uses
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
GC0000142A (en) An inhibitor of the formation of soluble human cd23.
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
HUP0201729A3 (en) Inhibitors of the integrin alpha v betha 6
HK1043660A1 (en) Metal-insulator-metal diodes and methods of manufacture
ZA200107015B (en) Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
HK1055288A1 (en) Novel aqueous composition and use of the same
TW553468U (en) Plate-spring and micro-actuating switch of the same
AU2574699A (en) Use of extracts from aristolochia in the treatment of aids
NO20005856L (en) Use of 1,1-dioxo-perhydro-1,2,4-thiadiazines
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.

Legal Events

Date Code Title Description
AVOD Application void